Login to Your Account

Evotec Gets $15M Up Front in Bayer Endometriosis Pact

By Cormac Sheridan
Staff Writer

Wednesday, October 3, 2012
Evotec AG is pocketing €12 million (US$15.5 million) up front and could receive up to €580 million more in preclinical, clinical and commercial milestones from a drug discovery alliance focused on endometriosis with Bayer Pharma AG.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription